GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men and women of no child beading potential to investigate repeated doses of the study medicine. The study will investigate the following questions, do repeated doses of the study medicine have any important side effects when taken by mouth? How much of the study medicine gets into the bloodstream, and how quickly does the body get rid of it? Does the study medicine affect memory, attention and problem-solving skills? What are the effects when the study medicine and dextromethorphan are taken together.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
48
Oral dose in liquid or tablet formulation
30mg Oral dose
To match GSK1034702
GSK Investigational Site
London, United Kingdom
Safety and tolerability endpoints consisting of: AEs; 12-lead ECG; 12 lead digital Holter and lead II telemetry; vital signs; clinical laboratory evaluations.
Time frame: Up to 28 days
GSK1034702 PK parameters: Cmax; tmax; AUC(0-t)
Time frame: Up to 28 days
Dextromethorphan PK parameters: Cmax; tmax; AUC(0-t).
Time frame: Day -2, 1 and 14
Effects on Cognitive tests.
Time frame: Up to day 28
Effects on salivary secretion
Time frame: up to 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.